Skip to main content
. 2019 Aug 28;20(17):4217. doi: 10.3390/ijms20174217

Figure 4.

Figure 4

Effects of PVN pretreatment of AM receptor antagonist AM22-52, or CGRP antagonist CGRP8-37 on RSNA and MAP responses to IMD (50 pM) in the PVN of OH rats (A,B); effects of AM22-52 pretreatment on IMD (50 pM) responses to Ang II (0.3 nM)-induced sympathetic activation in the PVN of OH rats (C,D); and PVN pretreatment with superoxide scavenger Tempol, AT1R antagonist Lorsatan and NADPH oxidase inhibitor Apo on RSNA and MAP responses to Ang II (0.3 nM) in the PVN of OH rats (E,F). Values are mean ± SEM. * p < 0.05 versus saline + saline; # p < 0.05 versus saline + IMD (A,B). * p < 0.05 versus saline + saline + AM22-52 or saline + saline + Ang II; # p < 0.05 versus saline + IMD + Ang II (C,D). * p < 0.05 versus saline + Ang II (E,F). n = 6 for each group.